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Abstract23
Recent human fatalities from avian-origin H10N8 influenza virus infection raise24
concerns about the threat of this virus subtype to public health. To investigate genetic25
adaptation of H10 avian influenza viruses in mammals, we generated26
a mouse-adapted avian H10N7 variant (A/mallard/Beijing/27/2011-MA, [BJ27-MA])27
through nine serial passages in mice. Mice infected with BJ27-MA virus died by 628
days post-infection and showed neuronal infection in contrast to parental virus which29
elicited no overt symptoms. Sequence analysis showed the absence of the widely30
recognized mammalian adaptation markers of E627K and D701N in PB2 in the31
mouse-adapted strain; instead five amino acid mutations were identified: E158G and32
M631L in PB2, G218E in HA (H3 numbering), and K110E and S453I in NA.33
Neurovirulence of BJ27-MA virus necessitated the combined presence of the PB2 and34
NAmutations. Mutations M631L and E158G of PB2 and K110E of NA were required35
to mediate increased virus replication and severity of infection in mice and36
mammalian cells. PB2-M631L was functionally the most dominant mutation in that it37
strongly up-regulated viral polymerase activity and played a critical role in the38
enhancement of virus replication and disease severity in mice. K110E mutation in NA,39
on the other hand, significantly promoted NA enzymatic activity. These results40
indicate that the novel mutations in PB2 and NA genes are critical for the adaptation41
of avian H10N7 influenza virus in mice, which could serve as molecular signatures of42
virus transmission to mammalian hosts including humans.43
44
Importance45
The increasingly prevalent H10 subtype of avian influenza virus in China has46
recently been a source of human fatalities. We demonstrated that an avian H10N747
virus can readily be adapted to become highly pathogenic and neurotropic in mice.48
Mutations in PB2 and NA from the mouse-adapted virus (BJ27-MA) were the major49
determinants of enhanced pathogenicity of which mutation PB2-M631L was50
functionally most dominant. Although BJ27-MA virus lacked the well-known51
mammalian adapted mutations (namely PB2-E627K and PB2-D701N), PB2-M631L52
mutation enhanced viral polymerase activity, replication and pathogenicity of53
BJ27-MA virus in mice, indicating a novel adaptation strategy. These observations54
affirm the public health threat of avian H10 subtype influenza viruses and have55
implications in the assessment of potential mutant viruses that may cause severe56
infections in humans.57
58
Introduction59
Presently, avian influenza viruses (AIVs) cause great economic losses to the global60
poultry industry, which historically were major contributors to the 1918 H1N1, 195761
H2N2 and 1968 H3N2 virus pandemics (1). H5N1 and H9N2 influenza viruses, as the62
two principal subtypes circulating in poultry, are high on the list of candidates that63
could potentially cause another major human influenza outbreak (2, 3). However,64
recent human cases of emergent avian H7N9 virus infection challenge our65
understanding of the main subtypes of possible future pandemic human virus (4).66
Thus, contingency planning in the prevention and management of avian influenza67
virus infections in human should be based on a broad range of possible subtypes.68
Between November 2013 and February 2014, two fatal and one severe cases of69
human infections with a novel reassortant H10N8 virus in Jiangxi, China, were70
reported for the first time (5-7). Avian H10 virus subtype was firstly isolated from71
chickens in Germany in 1949 (8, 9); subsequently viruses bearing H10 hemagglutinin72
(HA) and different neuraminidase (NA) subtypes have become widely prevalent in73
wild birds and domestic poultry around the world (10-12). Since 1984, repeated74
infections or deaths of mammals with this subtype have been reported, such as the75
outbreaks of H10N4 virus in minks (13), H10N5 virus in domestic pigs (14), H10N876
virus in feral dogs (15) and H10N7 virus in harbor seals (16-18). Human cases of H1077
virus infections had occurred sporadically in several other countries. For example,78
H10N7 viruses had caused a number of human infections in Egypt in 2004 (19). In79
March 2010, H10N7 virus infection was identified in two abattoir workers in a80
commercial poultry farm in Australia who showed conjunctivitis and minor upper81
respiratory tract symptoms (12). In the USA, serological evidence of exposure to H1082
virus subtype was confirmed in turkey workers (20). The repeated human cases of83
H10 virus infections coupled with the prevalence of H10 viruses in birds raise84
concerns that this particular subtype could pose increasing threat to human and animal85
health. However, the molecular adaptations of H10 influenza viruses in mammals are86
largely unknown.87
Adaptation is considered to be a primary driver in evolution, and the process of88
natural selection of influenza A viruses in experimental mice appears also to hold true89
for humans (21). Several adaptation studies of human H3N2, pandemic 2009 H1N1,90
avian H9N2 and H6N6 influenza viruses in mice have provided better understanding91
of molecular determinants of virus pathogenicity in mammals including humans92
(22-26). Here, to explore the genetic adaptations of H10 AIV subtype in mammals, we93
serially passaged a low-pathogenicity avian-derived H10N7 virus in mice. We found94
that mouse-adapted H10N7 virus acquired high pathogenicity status causing fatal95
infection and neurovirulence. The well-known mammalian adaptation markers96
PB2-E627K and PB2-D701N (27, 28) were not found in the mouse-adapted strain, but97
amino acid substitution PB2-M631L was a dominant contributor to virus virulence.98
99
Materials and methods100
Ethics statement101
All animal work was approved by the Beijing Association for Science and102
Technology (approval ID SYXK [Beijing] 2007-0023) and conducted in accordance103
with the Beijing Laboratory Animal Welfare and Ethics guidelines, as issued by the104
Beijing Administration Committee of Laboratory Animals, and in accordance with the105
China Agricultural University Institutional Animal Care and Use Committee106
guidelines (ID: SKLAB-B-2010-003).107
Viruses and cells108
The H10N7 virus A/mallard/Beijing/27/2011 (BJ27) was isolated in Beijing, China109
and propagated in the allantoic cavities of 10-day-old specific-pathogen-free (SPF)110
embryonated chicken eggs (Merial, Beijing, China) at 37°C for 72 h. Allantoic fluid111
containing virus was harvested, aliquoted and frozen at -80°C for later use. Viruses112
were titrated in MDCK cells to determine the 50% tissue culture infectious dose113
(TCID50) by the Reed and Muench method (29). Human embryonic kidney (293T),114
human pulmonary adenocarcinoma (A549), Madin Darby canine kidney (MDCK) and115
mouse neuroblastoma N2a (N2a) cells were maintained in Dulbecco’s modified116
Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS,117
Gibco), 100 units/ml of penicillin, and 100 μg/ml of streptomycin at 37°C in 5% CO2118
atmosphere.119
Adaptation of the BJ27 virus in mice120
Six 6-week-old female BALB/c mice (Beijing Experimental Animal Center) were121
anesthetized with Zoletil 50 (tiletamine-zolazepam; Virbac S.A., Garros, France) and122
inoculated intranasally with 50 μl of allantoic fluid containing BJ27 virus. At 3 days123
post-inoculation (dpi), three mice were euthanized and the lungs were harvested and124
homogenized in 1 ml of sterile cold phosphate-buffered saline (PBS). The125
homogenate was centrifuged at 6,000 × g for 5 min at 4°C and filtered through a126
0.22-μm-pore-size cellulose acetate filter (Millipore, USA). Fifty μl of filtered127
homogenate were used as inoculum per mouse for the next passage (passage 2 [P2]).128
The remaining three mice were monitored daily for clinical symptoms. At 9 passages129
(P9), the virus in the lung homogenate was subjected to three rounds of plaque130
purification in MDCK cells, and the cloned virus, designated BJ27-MA, was131
amplified once in 10-day-old SPF embryonated eggs for 72 h at 37°C, as previously132
described (30).133
Sequence analysis134
Viral RNA was extracted from allantoic fluid containing plaque-purified BJ27-MA.135
The eight virus genes were amplified by reverse transcription-PCR (RT-PCR) and136
sequenced. Adaptive mutations arising from serial passage were identified by137
comparing consensus BJ27-MA and wild type BJ27 sequences.138
Plasmid construction and virus rescue139
The eight gene segments of BJ27 and BJ27-MA were amplified by RT-PCR and140
cloned into the expression plasmid, PHW2000. Mutations of interest in the PB2, HA141
and NA gene were introduced by PCR-based site-directed mutagenesis with primer142
pairs containing point mutations. All constructs were sequenced to confirm mutational143
changes.144
Reassortant viruses between BJ27 and BJ27-MA were generated by reverse145
genetics as described previously (31). Briefly, 0.5 μg of each gene segment plasmid146
was mixed together and incubated with 8 μl of TransIT-LT1 reagent (Mirus Bio, USA)147
at 20°C for 30 min. The TransIT-LT1-DNA mixture was transferred to 70% confluent148
293T/MDCK co-cultured monolayers and incubated at 37°C with 5% CO2. Six hours149
post-transfection, the supernatants were replaced with 2 ml of Opti-MEM containing150
2 μg/ml TPCK-treated trypsin (Sigma-Aldrich). Forty-eight hours post-transfection,151
the cell supernatants were harvested and inoculated into 10-day-old SPF embryonated152
eggs and incubated for 72 h at 37°C to prepare a virus stock. Viral RNAwas extracted153
and analyzed by RT-PCR, and each viral segment was sequenced to confirm identity.154
Virus titers were determined by TCID50 assay on MDCK cells.155
Mouse experiments156
Groups of eleven 6-week-old female BALB/c mice (Beijing Experimental Animal157
Center) were anesthetized with Zoletil 50 (tiletamine-zolazepam; Virbac S.A., Garros,158
France) and inoculated intranasally with 105.5 TCID50 of viruses in 50 μl PBS. Three159
mice in each group were euthanized at 3 and 5 dpi; lungs, brains, spleens, kidneys and160
livers were collected for virus titration in MDCK cells. The remaining five mice in161
each group were monitored for weight loss and mortality for 14 days. Mice that lost162
more than 30% of their body weight were humanely euthanized. To determine the163
fifty percent mouse lethal dose (MLD50), groups of three 6-week-old female mice164
anesthetized with Zoletil 50 and inoculated intranasally with 50 μl of 10-fold serial165
dilutions of viruses in PBS. The mice were monitored for 14 days. MLD50 was166
calculated and expressed in TCID50. For histopathology and immunohistological167
analysis, mouse lungs and brains collected at 5 dpi were fixed in 10%168
phosphate-buffered formalin, embedded in paraffin, then cut into 5 mm-thick sections169
and stained with haematoxylin and eosin (H&E) or immunostained with a mouse170
monoclonal antibody specific for influenza A virus NP (Biorbyt, UK).171
Viral growth kinetics172
Selected recombinant viruses were inoculated onto MDCK cell monolayers (at173
multiplicity of infection [MOI] of 0.01), A549 cell monolayers (at MOI of 0.1) or N2a174
cell monolayers (at MOI of 0.1) in serum-free DMEM containing 1 μg/ml175
TPCK-treated trypsin and incubated at 37°C with 5% CO2 atmosphere. Cell176
supernatants were harvested at 12, 24, 36, 48, 60 and 72 hours post-inoculation (hpi)177
and titrated on MDCK cells in 96-well plates. Three independent experiments were178
performed for each virus.179
Polymerase activity assay180
The PB2, PB1, PA and NP gene segments of BJ27, BJ27-MA and BJ27-PB2181
mutants were individually inserted into pCDNA3.1 plasmid. PB2, PB1, PA and NP182
plasmids (125 ng each) were transfected to sixty percent confluent 293T cells,183
together with fire-fly luciferase reporter plasmid pYH-Luci (10 ng) and internal184
control plasmid expressing renilla luciferase (2.5 ng). After 24 hours of transfection,185
cell lysate was prepared with Dual Luciferase Reporter Assay System (Promega) and186
luciferase activity was measured using GloMax 96 microplate luminometer187
(Promega).188
Western blotting189
PB2 expression levels in different transfection groups were determined by Western190
blotting. Total cell protein lysates were extracted from transfected 293T cells with191
CA630 lysis buffer (150 mM NaCl, 1% CA630 detergent, 50 mM Tris base [pH 8.0]).192
Cellular proteins were separated by 12% sodium dodecyl sulfate-polyacrylamide gel193
electrophoresis (SDS-PAGE) and transferred to a polyvinylidenedifluoride (PVDF)194
membrane (Amersham Biosciences, Germany). Each PVDF membrane was blocked195
with 0.1% Tween 20 and 5% nonfat dry milk in Tris-buffered saline and subsequently196
incubated with a primary antibody. Primary antibodies used were specific for197
influenza A virus PB2 (ThermoFisher, USA) and β-actin (Beyotime, China).198
Secondary antibody was horseradish peroxidase (HRP)–conjugated anti-rabbit or199
-mouse antibody (Beyotime, China). HRP presence was detected using a Western200
Lightning chemiluminescence kit (Amersham Pharmacia, Freiburg, Germany),201
following the manufacturer’s protocols.202
Neuraminidase (NA) activity assay with substrate 4-MU-NANA203
NA activity assays using the soluble substrate MUNANA (Sigma, Germany) were204
performed as previously described (32). Briefly, virus was diluted to 106 TCID50/ml205
and 50 μl was added to each well of a black 96-well plate (CoStar). Concentrations of206
MUNANA substrate ranging from 2.0 μM to 200 μM were used. When cleaved by207
the viral NA, MUNANA produces a fluorescent product. Fluorescence was quantified208
using a Biotek Synergy H1 plate reader every 3 minutes over the course of 45 minutes.209
Fluorescence curves were then fitted to the Michaelis-Menton equation to determine210
values of Vmax and Km. Each experiment comprised triplicate samples of each virus.211
Statistical analyses212
All statistical analyses were performed using GraphPad Prism Software Version213
5.00 (GraphPad Software Inc., San Diego, CA, USA). Statistically significant214
differences between experimental groups were determined using the analysis of215
variance (ANOVA). Differences were considered statistically significant at P < 0.05.216
Nucleotide sequence accession numbers217
The nucleotide sequences of the eight gene segments of H10N7 are available from218
GenBank under accession numbers: KX898962 for PB2, KX898963 for PB1,219
KX898964 for PA, KX898965 for HA, KX898966 for NP, KX898967 for NA,220
KX898968 for M, and KX898969 for NS.221
222
Results223
Adaptation of avian H10N7 influenza virus in mice224
To mimic the adaptation of avian H10 subtype influenza virus in mammalian hosts,225
A/mallard/Beijing/27/2011 H10N7 virus (BJ27) was serially passaged in murine host226
by intranasal inoculation of 105.5 TCID50 of virus per mouse. Mice at passage 1 (P1)227
infected with wild type BJ27 did not show overt clinical sign. At P5, infected mice228
showed mild clinical signs, including decreased activity and ruffled coat. At P9 and229
P10, mice displayed severe clinical symptoms of respiratory distress, inactivity and230
inappetence; all infected mice died by 5 dpi (data not shown), indicating significant231
increase in pathogenicity. P9 virus from lung homogenate was plaque purified three232
times in MDCK cells and designated BJ27-MA.233
Mouse-adapted H10N7 virus exhibited enhanced pathogenicity and234
neurovirulence235
BALB/c mice were infected, in two groups of eleven mice each, with 105.5 TCID50236
of BJ27 or BJ27-MA virus to compare virus pathogenicity. BJ27-MA virus caused237
dramatic weight loss in infected mice and all were dead by 6 dpi, while mice infected238
with BJ27 showed modest weight loss of 8.7% and recovery weight gain from 7 dpi239
(Fig. 1A and B). To determine whether the differences in pathogenicity between BJ27240
and BJ27-MA virus were due to altered virus replication, groups of three BALB/c241
mice were euthanized at 3 and 5 dpi respectively, and virus titers in lung and brain242
were determined. As shown in Fig 1C and D, mouse-adapted BJ27-MA virus243
replicated to higher titers in the lungs than wild type BJ27 virus at 3 and 5 dpi.244
Furthermore, BJ27-MA virus was isolated from brains of infected mice in rising titers245
from mean titer of 2.1 log10 TCID50 /ml at 3 dpi to 2.8 log10 TCID50 /ml at 5 dpi. No246
virus was isolated from brains of BJ27 virus infected mice. Therefore, the247
mouse-adapted BJ27-MA virus has acquired neurotropism which would have248
contributed to the severity of infection in mice.249
Genetic changes in adapted BJ27-MA virus250
To identify potential segments and amino acid substitutions that are responsible for251
increased pathogenicity and replication of BJ27-MA virus in mice, the consensus252
sequence of thirty virus clones was determined. Interestingly, the most common253
mammalian adaptation determinants of PB2-E627K and PB2-D701N (27, 28), did not254
appear in any of the thirty clones, indicating that other viable adaptations were present255
in the BJ27-MA virus. Here, five conserved amino acid mutations that could be linked256
to increased pathogenicity were identified in 3 virus segments of the BJ27-MA virus257
as PB2-E158G, PB2-M631L, HA-G218E (H3 numbering), NA-K110E and258
NA-S453I.259
PB2-E158G mutation resides in the amino-terminal NP binding region (1–269aa)260
(23), and PB2-M631L lies in the PB2-PB1 and PB2-NP interaction regions (25). HA261
G218E is located near the 220-loop of the globular head HA1 domain (33).262
NA-K110E and NA-S453I reside in the amino-terminal and carboxyl-terminal region263
of NA protein, respectively; both are located in the interface of tetrameric structure of264
NA protein (34).265
PB2 and NA segments in BJ27-MA virus conferred increased pathogenicity and266
replication capacity in mice267
To identify virus segments from the BJ27-MA virus that confer increased268
pathogenicity in mice, a series of recombinant viruses were generated by reverse269
genetic based on wild type BJ27 (rBJ27) and BJ27-MA (rBJ27-MA) viruses.270
Recombinant viruses rBJ27-PB2, rBJ27-HA and rBJ27-NA were constructed in rBJ27271
virus background with the substituted segments of PB2, HA and NA, respectively,272
from the rBJ27-MA virus. Mice infected with recombinant viruses were monitored273
over 14 days for weight loss and survival rate. As shown in Fig. 2A and B, all of274
rBJ27 and rBJ27-HA viruses infected mice, similar to wild type BJ27 virus infection,275
survived with maximum 6.7% and 8.8% weight loss respectively. By contrast, mice276
infected with rBJ27-MA and rBJ27-PB2 viruses resulted in 25% to 31% weight loss277
and 100% mortality by 6 dpi. rBJ27-NA virus showed moderate increase in278
pathogenicity with 40% mortality. The MLD50 values also showed the same279
descending order of virus virulence: rBJ27-MA, rBJ27-PB2 (both MLD50, 4.75 log10280
TCID50) > rBJ27-NA (5.75 log10 TCID50) > rBJ27 and rBJ27-HA (>6.5 log10 TCID50)281
(Table 1). None of these segment recombinants was neurotropic although they were282
recovered from lungs and extrapulmonary organs (kidney and/or spleen) (Table 1).283
Thus, the adaptive PB2 and NA segments of BJ27-MA conferred increased virulence284
in wild type BJ27 virus background in mice.285
Combined PB2 and NA segments of BJ27-MA virus contributed to286
neurovirulence287
Influenza virus replication in the central nervous system (CNS) often leads to fatal288
outcome (35-37). Although mouse-adapted BJ27-MA virus was able to efficiently289
replicate in murine brain, none of the above single segment recombinant viruses was290
found in the brain of infected mice (Table 1). Next, we generated three291
double-segment recombinant viruses based on the rBJ27 backbone: rBJ27-PB2/HA292
virus, rBJ27-PB2/NA virus and rBJ27-HA/NA virus. As shown in Table 2, only293
rBJ27-PB2/NA virus was recovered from infected murine brains at 3 and 5 dpi which294
produced MLD50 value and viral loads similar to those of rBJ27-MA virus at each295
time point. Viral NP was readily detected in neurons of mice infected separately with296
rBJ27-MA and rBJ27-PB2/NA viruses (Fig. 3A). These data demonstrated that the297
combined PB2 and NA segments of rBJ27-MA contributed to its neurovirulence in298
mice.299
The ability of double segment recombinant viruses to replicate in neural tissue was300
assessed in mouse neuroblastoma N2a cells which has been used to study the301
replication of neurotropic viruses (38). Only rBJ27-MA and rBJ27-PB2/NA viruses302
showed up to 15-fold increased virus output relative to rBJ27 virus at 24 and/or 36 hpi303
(Fig. 3B). The other viruses (rBJ27-PB2/HA and rBJ27-HA/NA) showed no304
significant difference in virus titers at all time points. Therefore, the combined PB2305
and NA segments also enhanced the replication of rBJ27-MA virus in neural cells.306
PB2-M631L, PB2-E158G and NA-K110E contributed to severe BJ27-MA virus307
infection308
To pinpoint the contribution of the single mutations in PB2 and NA to the increased309
pathogenicity of BJ27-MA, four point mutant viruses were generated with the rBJ27310
backbone as rBJ27-PB2/E158G, rBJ27-PB2/M631L, rBJ27-NA/K110E and311
rBJ27-NA/S453I viruses. Virus rBJ27-PB2/M631L was most virulent in that all312
infected mice died before 8 dpi (Fig. 2C and D). Virus rBJ27-PB2/E158G and313
rBJ27-NA/K110E caused moderate weight loss of around 13.3% without fatality.314
Virus NA-S453I and wild type rBJ27 were least pathogenic and caused little weight315
loss. MLD50was highest with PB2-M631L virus (4.75 log10 TCID50) relative to all the316
other viruses (>6.5 log10 TCID50) (Table 1). Compared with rBJ27, the viral titers of317
rBJ27-PB2/M631L, rBJ27-PB2/E158G and rBJ27-NA/K110E in murine lungs were318
significantly higher at 3 and/or 5 dpi (Table 1). Virus rBJ27-PB2/M631L produced319
the highest virus titers. However, none of the four point mutation viruses showed320
extrapulmonary infection in liver, spleen, kidney or brain.321
Histopathological findings of lung tissues taken at 5 dpi gave a severity picture that322
was similar to the pathogenicity results (Fig. 2E). Virus rBJ27-PB2/M631L and323
rBJ27-MA elicited the most severe lung lesions of edema, inflammatory infiltrates,324
interstitial pneumonia and bronchopneumonia. Lungs from rBJ27-PB2/E158G and325
rBJ27-NA/K110E virus infection showed less severe bronchopneumonic changes.326
Almost no lung lesion was detected from infection with rBJ27 and rBJ27-NA/S453I327
viruses except for some thickening of alveolar wall and mild infiltration of328
inflammatory cells.329
We next compared the replication of the four mutant viruses in MDCK and A549330
cells, infected at MOI of 0.01 or 0.1 respectively, over 72 h. In MDCK cells (Fig. 4A),331
rBJ27-MA virus showed higher output (up to 56-fold higher) than the parental rBJ27332
from 24 to 72 hpi, and PB2/M631L mutation increased the replication of rBJ27 virus333
at 36 hpi (both P < 0.05). Replication of rBJ27-PB2/E158G, rBJ27-NA/K110E and334
rBJ27-NA/S453I viruses was similar to that of rBJ27 virus. In A549 cells, the335
rBJ27-MA virus also showed higher output from 24 to 60 hpi, and rBJ27-PB2/M631L,336
rBJ27-PB2/E158G and rBJ27-NA/K110E viruses produced more progeny virus at 24337
or 36 hpi than rBJ27 virus (all P < 0.05) (Fig. 4B). Therefore, in summary,338
PB2-M631L, PB2-E158G and NA-K110E mutations in rBJ27 virus backbone339
conferred more severe infection than wild type rBJ27 virus in mice and mammalian340
cells, with PB2-M631L mutation being the most potent determinant.341
PB2-M631L and PB2-E158G mutations enhanced polymerase activity of342
BJ27-MA virus343
PB2 is one of the components of ribonucleoprotein (RNP). RNP polymerase344
activity has been shown to catalyze viral transcription and genomic replication, which345
correlate with viral replication and pathogenicity in hosts (39). To evaluate whether346
the mutations of PB2-E158G and PB2-M631L affect viral polymerase activity, we347
generated two mutant RNP complexes under the background of the RNP of rBJ27,348
and measured their polymerase activities in 293T cells by a luciferase minigenome349
assay (Fig. 5). RNP polymerase activity with single E158G or M631L mutation was350
28 or 62 times higher, respectively, than that of wild type rBJ27 RNP complex;351
combined E158G and M631L PB2 mutations induced 75 times higher activity than352
with the rBJ27 RNP complex (all P < 0.05). Western blotting, based on protein lysates353
derived from 293T cells transfected with the different PB2 mutant plasmids in RNP354
polymerase assays, showed comparable PB2 protein expression, which indicated that355
the differences in polymerase activity were not due to levels of protein expression356
(Fig. 5). Collectively, the raised polymerase activity conferred by PB2-M631L and357
PB2-E158G mutations correlate with their severity of virus replication in mice and358
mammalian cells, and suggest that elevated polymerase activity, rather than protein,359
mediated the increased replication of BJ27-MA virus; the single M631L mutation in360
PB2 appeared as a major contributor.361
NA-K110E increased NA enzymatic activity362
NA enzymatic activity is associated with influenza virus replication and363
pathogenicity (40). The two amino acid mutations (K110E and S453I) in the364
BJ27-MA NA protein were evaluated for NA enzymatic activity as described365
previously (32). Based on Km values, we found that the NA-K110E mutation caused a366
significant increase as did the mutant segment (rBJ27-NA with double mutations) in367
substrate affinity (Table 3). Similarly, Vmax, which was determined by both the specific368
activity and the amount of enzyme in the reaction mixture, was significantly higher369
with the K110E mutation than with wild type rBJ27 virus (P < 0.05). The Vmax of370
rBJ27-NA/S453I virus was increased but not significantly higher than rBJ27 virus.371
Thus, NA-K110E mutation improved NA enzymatic activity, which would have372
contributed to the increased replication and pathogenicity of rBJ27-MA virus in mice.373
Discussion374
In this study, serial passage of avian H10N7 virus in mice resulted in dramatic375
acquisition of pathogenicity in terms of increase virus replication, virus dissemination376
that extended to the brain and high mortality rate. Five conserved mutations were377
identified in PB2, HA and NA genes of the passaged BJ27-MA virus (PB2-E158G,378
PB2-M631L, HA-G218E, NA-K110E and NA-S453I). The mutations in PB2 and NA379
genes significantly up-regulated viral polymerase activity and NA enzymatic activity380
respectively; their combined presence in BJ27-MA virus was necessary for381
neurovirulence. In particular, M631L mutation in PB2 was a major molecular382
determinant for the overall increase in virulence of the mouse-adapted H10N7 virus.383
PB2 gene plays important roles in the adaptation of influenza viruses from avian to384
mammals through increasing polymerase activity and viral replication (41).385
Polymerases of avian-origin generally have impaired function in human and other386
mammalian cells (39). To overcome this natural restriction, avian polymerases need to387
acquire mutations that lead to improved activity in mammalian hosts. E627K or388
D701N in PB2 is a common adaptive change of avian influenza viruses that cause389
mammals and human infections (27, 28, 42). In our mice adaptation study, in place of390
these reported mutations in the PB2 gene, E158G and M631L were identified to391
mediate the promotion of polymerase activity, virus pathogenicity and replication in392
mice. PB2-E158G was reported to be a pathogenic determinant of pandemic H1N1393
and avian H5 influenza viruses in mice (24). PB2-M631L is a novel and dominant394
pathogenic mutation not previously described. The structure of PB2 shows that395
position 631 is close to position 627 and located at the PB2-PB1 and PB2-NP396
interaction regions (22). From the isolates of human infection cases, PB2 sequence397
analysis found that nine avian H5N1 and two pandemic H1N1/2009 viruses possessed398
PB2-M631L but not E627K or D701N mutation, implying that PB2-M631L could be399
functionally important independent of E627K or D701N. Likewise, during the400
pH1N1/2009 virus outbreak in humans, the PB2-E627K mutation was absent; instead401
PB2-G590S/Q591R mutation was responsible for increased polymerase activity in402
human cells (43). Therefore, PB2-M631L could be a novel functional mutation in403
H10N7 virus adaptation in mammalian hosts.404
NA cleaves sialic acid from glycans on host cell and emerging virions, thus405
allowing unhindered release of progeny virus from infected cells (40). Several studies406
found that amino acid mutations or deletions in NA can affect NA enzymatic activity,407
which correlate with virus replication and pathogenicity in vitro or in vivo (44-46).408
Here, NA-K110E in BJ27-MA virus, acting as a novel mammalian mutation,409
significantly increased NA activity and viral replication in mice. We found that the410
two NA mutations (K110E and S453I) are located in the interface of tetrameric411
structure of NA (34) which may affect the formation of tetramer.412
Neurovirulence is not commonly observed in the adaptation of avian influenza413
viruses in mice (21-23, 42). Besides our H10N7 virus, another related virus (H10N8)414
was reported to acquire neurotropism after two passages in mice (42), suggesting that415
H10 subtype might be more able to gain the ability to replicate in mammalian brain.416
Clinically, CNS disease is a common extra-respiratory complication in humans417
induced by influenza virus. Patients with CNS manifestations are more likely to418
experience severe illness (35-37). In Australian and Texas, USA, 9.7% and 8.8%419
hospitalized children, respectively, infected with pH1N1/2009 virus had neurological420
complications (47, 48). Ying et al. also found that viruses with high replication ability421
in murine brain also possess high pathogenicity (49). The collective evidence422
indicates that high pathogenicity and neurovirulence could cooperate to promote423
fatalities in human cases of H10N8 virus infection. Molecular mechanism of influenza424
virus causing infection in the CNS is unclear. HA, NA and PB2 genes have been425
separately found to be critical to the neurovirulence of H1N1 or H5N1 viruses in426
mammalian hosts (50-53). However, in our present study, the viruses with single427
adapted PB2 or NA segment could not cause brain infection although when combined428
they replicated in the brain to a level comparable with rBJ27-MA virus which429
indicates that the synergistic effect of PB2 and NA is important for H10N7430
neurovirulence.431
In summary, our mouse adaptation study clearly shows that avian H10N7 virus can432
readily become highly virulent and neurotropic after limited passages in mice. We433
demonstrated that this enhanced pathogenicity was mediated by specific mutations in434
PB2 and NA genes; in particular PB2-M631L is a novel and critical determinant of435
virulence.436
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Figure legends640
FIG 1 Pathogenicity and replication of wild type (BJ27) and mouse-adapted641
(BJ27-MA) H10N7 viruses in mice. Six-week-old female BALB/c mice were642
inoculated with 105.5 TCID50 of the indicated viruses or mock infected with PBS. (A)643
Body weight changes over a 14-day period were plotted as percentage of body weight644
at 0 dpi (n = 5 per group). Data are presented as means ± SD of five individual mice.645
(B) Survival data expressed as percentage of mice infected with indicated virus. Mice646
that lost > 30% of their baseline weight were euthanized. BJ27 and BJ27-MA virus647
titers were determined in lungs (C) and brains (D) of infected mice (n = 3 per group).648
Data are presented as means ± SD of three individual mice. ＊ , the value is649
significantly different from that of BJ27 (P < 0.05, ANOVA).650
651
FIG 2 Relative virulence of different recombinant and mutant BJ27 (H10N7) viruses652
in mice. (A and C) Body weight changes in mice (n = 5) infected with 105.5 TCID50 of653
indicated viruses over a 14-day period, plotted as percentage of body weight at 0 dpi.654
Data are presented as means ± SD of five individual mice. (B and D) Survival data655
expressed as percentage of mice infected with indicated viruses. Mice that lost more656
than 30% of baseline weight were euthanized. (E) H&E examination was performed657
on the lungs of mice infected with indicated viruses at 5 dpi. Virus rBJ27-PB2/M631L658
and rBJ27-MA infection caused severe bronchopneumonia; rBJ27-PB2/E158G and659
rBJ27-NA/K110E infections produced moderate bronchopneumonia ； rBJ27 and660
rBJ27-NA/S453I infection caused almost no lung lesion. Scale bar, 200 μm.661
FIG 3 Neurovirulence of recombinant BJ27 (H10N7) viruses. (A) Sections of brains662
taken from mice 5 dpi with 105.5 TCID50 of indicated viruses were immunostained for663
viral NP (open arrow). Scale bar, 400 μm. (B) Growth kinetics of recombinant viruses664
in neuronal N2a cells. Confluent N2a cells were infected with indicated viruses at 0.1665
MOI. Data are presented as means ± SD of three independent experiments. ＊ , the666
value is significantly different from that of rBJ27 (P < 0.05, ANOVA).667
668
FIG 4 Growth kinetics of recombinant H10N7 viruses in MDCK and A549 cells.669
Confluent MDCK (A) or A549 (B) cells were infected with viruses as indicated at670
MOI of 0.01 or 0.1 respectively. Data are presented as means ± SD of three671
independent experiments. ＊, the value is significantly different from that of rBJ27 (P672
< 0.05, ANOVA).673
674
FIG 5 Polymerase activity of BJ27 with different PB2 mutations in minigenome675
assays. Luciferase activities were relative to wild type BJ27 set at 100%. Expression676
of PB2 and β-actin was detected by Western blotting. Data are presented as means ±677
SD of three independent experiments. ＊, the value is significantly different from that678
of BJ27 (P < 0.05, ANOVA).679
TABLE 1 Pathogenicity and replication of BJ27 (H10N7) recombinant and mutant viruses in mice
Average virus titer in sample a
Lung Brain Spleen Kidney Liver
Virus MLD50
(log10 TCID50)
3 dpi 5 dpi 3 dpi 5 dpi 3 dpi 5 dpi 3 dpi 5 dpi 3 dpi 5 dpi
rBJ27 >6.5 4.5±0.3 4.7±0.1 0/3 b 0/3 0/3 0/3 0/3 0/3 0/3 0/3
rBJ27-MA 4.75 6.5±0.3＊ 6.9±0.3＊ 2.1±0.4＊ 2.8±0.6＊ 2.3,1.8 c＊ 2.3,1.8＊ 0/3 2.9±0.3＊ 0/3 0/3
rBJ27-PB2 4.75 6.2±0.4＊ 6.6±0.3＊ 0/3 0/3 2.3＊ 0/3 0/3 2.2±0.6＊ 0/3 0/3
rBJ27-HA >6.5 5.0±0.4 5.4±0.3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
rBJ27-NA 5.75 5.5±0.1＊ 6.1±0.3＊ 0/3 0/3 1.8＊ 0/3 0/3 0/3 0/3 0/3
rBJ27-PB2/E158G >6.5 5.2±0.4＊ 5.5±0.3＊ 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
rBJ27-PB2/M631L 4.75 5.7±0.1＊ 6.3±0.1＊ 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
rBJ27-NA/K110E >6.5 5.2±0.3＊ 5.3±0.4 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
rBJ27-NA/S453I >6.5 4.9±0.4 5.3±0.1 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
a Mean virus titer in sample (log10 TCID50/ml) ± SD. The lower limit of detection was 100.75 TCID50/ml for each sample. ＊, virus titer of corresponding strains was
significantly higher than that of rBJ27 (P < 0.05, ANOVA).
b The number of samples with recovered viruses versus the number of total collected samples.
c The number(s) shows the virus titer in an individual infected mouse.
TABLE 2 Pathogenicity and replication of double-segment recombinant H10N7 viruses in murine
brain
Average virus titer in brain a
Virus MLD50 3 dpi 5 dpi
rBJ27 >6.5 0/3 b 0/3
rBJ27-MA 4.75 2.1±0.4 2.8±0.6
rBJ27-PB2/HA 5.25 0/3 0/3
rBJ27-PB2/NA 4.75 1.8,2.3 c 2.5±0.5
rBJ27-HA/NA 5.5 0/3 0/3
a Mean virus titer in sample (log10 TCID50/ml) ± SD. Lower limit of detection was 100.75
TCID50/ml in the brain.
b The number of samples with recovered viruses versus the number of total collected samples.
c The number(s) shows virus titer in an individual mouse.
TABLE 3 NA enzyme kinetics of mutant H10N7 viruses a
Virus Km (μM) Vmax Vmax ratio b
rBJ27 28.7±4.1 0.53±0.10 1.00
rBJ27-MA 14.8±1.8＊ 0.90±0.09＊ 1.70＊
rBJ27-NA 15.6±2.3＊ 0.86±0.06＊ 1.62＊
rBJ27-NA/K110E 17.8±1.5＊ 0.78±0.02＊ 1.47＊
rBJ27-NA/S453I 20.7±2.2 0.66±0.14 1.25
a A standardized virus dose of 106 TCID50/ml was used for the NA kinetics assay. The enzyme
kinetics data (standard deviation) were fit to the Michaelis-Menten equation by nonlinear
regression to determine the Michaelis constant (Km) and maximum velocity (Vmax) of substrate
conversion (in fluorescent units per second). ＊ , the value of corresponding strains was
significantly different from that of rBJ27 (P < 0.05, ANOVA).
b The ratio of the recombinant viruses versus rH10N7 virus Vmax values.
Figure legends
Fig. 1
FIG 1 Pathogenicity and replication of wild type (BJ27) and mouse-adapted
(BJ27-MA) H10N7 viruses in mice. Six-week-old female BALB/c mice were
inoculated with 105.5 TCID50 of the indicated viruses or mock infected with PBS. (A)
Body weight changes over a 14-day period were plotted as percentage of body weight
at 0 dpi (n = 5 per group). Data are presented as means ± SD of five individual mice.
(B) Survival data expressed as percentage of mice infected with indicated virus. Mice
that lost > 30% of their baseline weight were euthanized. BJ27 and BJ27-MA virus
titers were determined in lungs (C) and brains (D) of infected mice (n = 3 per group).
Data are presented as means ± SD of three individual mice. ＊ , the value is
significantly different from that of BJ27 (P < 0.05, ANOVA).
Fig. 2
FIG 2 Relative virulence of different recombinant and mutant BJ27 (H10N7) viruses
in mice. (A and C) Body weight changes in mice (n = 5) infected with 105.5 TCID50 of
indicated viruses over a 14-day period, plotted as percentage of body weight at 0 dpi.
Data are presented as means ± SD of five individual mice. (B and D) Survival data
expressed as percentage of mice infected with indicated viruses. Mice that lost more
than 30% of baseline weight were euthanized. (E) H&E examination was performed
on the lungs of mice infected with indicated viruses at 5 dpi. Virus rBJ27-PB2/M631L
and rBJ27-MA infection caused severe bronchopneumonia; rBJ27-PB2/E158G and
rBJ27-NA/K110E infections produced moderate bronchopneumonia; rBJ27 and
rBJ27-NA/S453I infection caused almost no lung lesion. Scale bar, 200 μm.
Fig. 3
FIG 3 Neurovirulence of recombinant BJ27 (H10N7) viruses. (A) Sections of brains
taken from mice at 5 dpi were immunostained for viral NP (open arrow). Scale bar,
400 μm. (B) Growth kinetics of recombinant viruses in neuronal N2a cells. Confluent
N2a cells were infected with indicated viruses at 0.1 MOI. Data are presented as
means ± SD of three independent experiments. ＊, the value is significantly different
from that of rBJ27 (P < 0.05, ANOVA).
Fig. 4
FIG 4 Growth kinetics of recombinant H10N7 viruses in MDCK and A549 cells.
Confluent MDCK (A) or A549 (B) cells were infected with viruses as indicated at
MOI of 0.01 or 0.1 respectively. Data are presented as means ± SD of three
independent experiments. ＊, the value is significantly different from that of rBJ27 (P
< 0.05, ANOVA).
Fig. 5
FIG 5 Polymerase activity of BJ27 with different PB2 mutations in minigenome
assays. Luciferase activities were relative to wild type BJ27 set at 100%. Expression
of PB2 and β-actin was detected by Western blotting. Data are presented as means ±
SD of three independent experiments. ＊, the value is significantly different from that
of BJ27 (P < 0.05, ANOVA).
